CreativeOne Wealth LLC Has $1.49 Million Position in Merit Medical Systems, Inc. (NASDAQ:MMSI)

CreativeOne Wealth LLC raised its position in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 190.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 15,433 shares of the medical instruments supplier’s stock after purchasing an additional 10,113 shares during the period. CreativeOne Wealth LLC’s holdings in Merit Medical Systems were worth $1,493,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the company. NewSquare Capital LLC bought a new stake in shares of Merit Medical Systems in the 4th quarter valued at $32,000. Kohmann Bosshard Financial Services LLC acquired a new position in Merit Medical Systems in the fourth quarter valued at about $52,000. Federated Hermes Inc. increased its holdings in shares of Merit Medical Systems by 139.1% in the fourth quarter. Federated Hermes Inc. now owns 655 shares of the medical instruments supplier’s stock worth $63,000 after acquiring an additional 381 shares in the last quarter. Smartleaf Asset Management LLC raised its position in shares of Merit Medical Systems by 237.7% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,388 shares of the medical instruments supplier’s stock worth $134,000 after purchasing an additional 977 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in shares of Merit Medical Systems by 14.7% during the 4th quarter. GAMMA Investing LLC now owns 1,494 shares of the medical instruments supplier’s stock valued at $144,000 after purchasing an additional 191 shares in the last quarter. 99.66% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Merit Medical Systems

In other news, Director Stephen C. Evans sold 5,000 shares of Merit Medical Systems stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $105.31, for a total value of $526,550.00. Following the completion of the transaction, the director now owns 4,657 shares of the company’s stock, valued at $490,428.67. This trade represents a 51.78 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Brian G. Lloyd sold 30,000 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $102.90, for a total transaction of $3,087,000.00. Following the completion of the sale, the insider now directly owns 38,945 shares in the company, valued at approximately $4,007,440.50. The trade was a 43.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 109,132 shares of company stock valued at $11,139,521. 3.70% of the stock is owned by insiders.

Merit Medical Systems Stock Down 1.4 %

Shares of MMSI stock opened at $91.96 on Wednesday. The firm’s fifty day moving average price is $101.26 and its two-hundred day moving average price is $100.79. Merit Medical Systems, Inc. has a 1 year low of $70.70 and a 1 year high of $111.45. The company has a current ratio of 5.36, a quick ratio of 3.82 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $5.43 billion, a P/E ratio of 45.08, a PEG ratio of 2.34 and a beta of 0.85.

Analysts Set New Price Targets

A number of research firms recently issued reports on MMSI. Raymond James increased their target price on Merit Medical Systems from $105.00 to $110.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 31st. Canaccord Genuity Group lowered their price objective on shares of Merit Medical Systems from $128.00 to $127.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Barrington Research reaffirmed an “outperform” rating and issued a $111.00 price objective on shares of Merit Medical Systems in a research report on Friday, April 11th. JPMorgan Chase & Co. assumed coverage on shares of Merit Medical Systems in a research note on Friday, March 28th. They issued an “overweight” rating and a $120.00 target price for the company. Finally, Wells Fargo & Company dropped their price target on Merit Medical Systems from $120.00 to $117.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $114.33.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.